PhD Student
Email: mpryor [at] mit . edu
she/her/hers
Layer-by-Layer Nanoparticles for Targeting Minimal Residual Disease in Ovarian Cancer
The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed at late stages in disease progression (stage III/IV), which leads to extremely low cure rates with current surgical and chemotherapy interventions. Further, of the meager surviving patient population, over 80% will experience relapse due to the persistence of a small, clinically undetectable population of chemotherapy-resistant cancer cells known as minimal residual disease (MRD), and in this event, the disease is considered incurable. In this work, I engineer layer-by-layer nanoparticles (LbL NPs) for the targeted delivery of immunotherapies to ovarian cancer at the MRD stage.